纳洛酮心脏骤停决策工具的验证:识别阿片类药物相关心脏骤停
本研究在加拿大安大略省2020-2021年EMS接诊且有心法医记录的院外心脏骤停患者中,外部验证NACARDI工具(年龄+未目击骤停两项标准),分别评估年龄<50岁(NACARDI-50)和<60岁(NACARDI-60)两个切点。2904例无明确病因的OHCA中791例有法医评估,121例(15.3%)被裁定为隐匿性阿片相关OHCA。NACARDI-60敏感性82.6%(95%CI 74.9-88.4%)、特异性77.1%(95%CI 73.8-80.1%)、阴性预测值96.1%(95%CI 94.1-97.4%)、阳性预测值39.4%(95%CI 33.6-45.5%);NACARDI-50敏感性63.6%、特异性89.3%。两切点ROC曲线均显示优秀判别力。结论认为NACARDI敏感性和特异性足以辅助院前实时识别隐匿性阿片相关OHCA,并可能指导针对性干预。
要点
- NACARDI由两项标准组成:患者年龄和未目击心脏骤停,用于EMS提供者复苏期间快速识别隐匿性阿片相关OHCA。
- NACARDI-60(年龄<60岁)敏感性82.6%(95%CI 74.9-88.4%)、特异性77.1%(95%CI 73.8-80.1%)、阴性预测值96.1%(95%CI 94.1-97.4%)、阳性预测值39.4%(95%CI 33.6-45.5%)。
- NACARDI-50(年龄<50岁)敏感性63.6%(95%CI 54.4-72.2%)、特异性89.3%(95%CI 86.7-91.5%)、阴性预测值93.2%(95%CI 90.9-95.0%)、阳性预测值51.7%(95%CI 43.4-59.9%)。
- 在791例经法医评估的无明显病因OHCA中,121例(15.3%)被裁定为隐匿性阿片相关OHCA。
- NACARDI-50和NACARDI-60的ROC曲线均显示对隐匿性阿片相关OHCA具有优秀判别力。
适用人群与场景
- EMS接诊的院外心脏骤停患者,年龄≥18岁,且心脏骤停死亡并有法医记录。
- 排除EMS怀疑药物过量或已知心脏骤停病因的患者。
诊断标准与关键阈值
- NACARDI包含两项标准:患者年龄和未目击心脏骤停;验证的两个年龄切点为<50岁(NACARDI-50)和<60岁(NACARDI-60)。
研究设计与关键结果
- 研究类型:回顾性外部验证,使用加拿大安大略省2020-2021年EMS接诊OHCA患者和法医记录数据。
- 样本量:2904例无明确病因的OHCA中,791例有法医评估,121例(15.3%)被裁定为隐匿性阿片相关OHCA。
- NACARDI-60:敏感性82.6%(95%CI 74.9-88.4%),特异性77.1%(95%CI 73.8-80.1%),阴性预测值96.1%(95%CI 94.1-97.4%),阳性预测值39.4%(95%CI 33.6-45.5%)。
- NACARDI-50:敏感性63.6%(95%CI 54.4-72.2%),特异性89.3%(95%CI 86.7-91.5%),阴性预测值93.2%(95%CI 90.9-95.0%),阳性预测值51.7%(95%CI 43.4-59.9%)。
- NACARDI-50和NACARDI-60的ROC曲线均显示对隐匿性阿片相关OHCA具有优秀判别力。
证据类型、等级与局限
- 证据类型:回顾性外部验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为NACARDI的敏感性和特异性足以辅助院前实时识别隐匿性阿片相关OHCA(NACARDI-60敏感性82.6%、特异性77.1%;NACARDI-50敏感性63.6%、特异性89.3%)。
- 作者认为NACARDI有潜力指导针对阿片相关OHCA的靶向干预。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Up to fifteen percent of out-of-hospital cardiac arrests (OHCAs) are precipitated by occult drug overdose - cases without history or evidence of drug use that are often attributed to a non-overdose cause. The NAloxone Cardiac ARrest Decision Instrument (NACARDI) was derived to help emergency medical service (EMS) providers rapidly identify patients at higher risk of occult opioid-associated (OA)-OHCAs during resuscitation. In this analysis we externally validate NACARDI in an independent cohort of OHCA patients.
METHODS: We conducted a retrospective validation using data from EMS-attended OHCA patients and coroner records in Ontario, Canada between 2020-2021. Inclusion criteria were age ≥18 years and OHCA death with a coroner record. Exclusion criteria were EMS-suspected drug overdose or known cause of the OHCA. NACARDI consists of two criteria: patient age and unwitnessed cardiac arrest. Two cut-offs for patient age were assessed for this validation: <50 years (NACARDI-50) and <60 years (NACARDI-60). The primary outcome was coroner adjudicated cause of death. We calculated screening characteristics and receiver operating characteristic (ROC) curves using standard formulae.
RESULTS: Of 2904 OHCA cases without an obvious cause, 791 had coroner evaluations and 121 (15.3 %) were adjudicated as occult OA-OHCA. NACARDI-60 had: sensitivity 82.6 % (95 %CI 74.9-88.4 %), specificity 77.1 % (95 %CI 73.8-80.1 %), negative predictive value 96.1 % (95 %CI 94.1-97.4 %), and positive predictive value 39.4 % (95 %CI 33.6-45.5 %). NACARDI-50 had: sensitivity 63.6 % (95 %CI 54.4-72.2 %), specificity 89.3 % (95 %CI 86.7-91.5 %), negative predictive value 93.2 % (95 %CI 90.9-95.0 %), and positive predictive value 51.7 % (95 %CI 43.4-59.9 %). ROC curves for both NACARDI-50 and NACARDI-60 demonstrated excellent discrimination for occult OA-OHCA.
CONCLUSION: In this external validation cohort, NACARDI had a sensitivity and specificity sufficiently high to aid in the real-time identification of occult OA-OHCA in the field. NACARDI has the potential to guide targeted interventions for OA-OHCA.
参考来源
- Dillon DG, Allan KS, Montoy JCC, et al. Validation of the naloxone cardiac arrest decision instrument for identifying opioid-associated cardiac arrests. Resuscitation. 2025. PMID: 41062055. doi:10.1016/j.resuscitation.2025.110851
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。